According to the Panel, immunotherapy must not be considered as a first option when treating RET- (and NTRK-) mutated NSCLC, even when PD-L1 ≥ 50%, as targeted therapies result in better outcomes [50,51]; on the other hand, MET, BRAF (V600), and HER2 mutations do not have a role in directing first-line treatments towards ICI monotherapy or chemoimmunotherapy, regardless of PD-L1 expression. Here, BRAF is linked to non-small cell lung carcinoma.